At present, only one clinical trial has been activated in AML patients: the AARON study (NCT04913922), which will test the safety and tolerability of a triplet of AZA, nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) in patients with relapsed/refractory AML and newly diagnosed AML aged > 65 years: recruitment started in November 2022; no results are still available. This evidence concerns the gene LAG3 and acute myeloid leukemia.